The 3rd ISG/SSG meeting

Cetraro
Grand Hotel San Michele

April 26–29, 2006

Program
Preface

We wish all members of the Italian and Scandinavian Sarcoma Groups and members of other European sarcoma groups welcome to our 3rd joint meeting in Cetraro, April 27-29, 2006.

Our collaboration started with the introduction of the two comprehensive treatment and research protocols (ISG/SSG I-II) for high-grade osteosarcoma of the extremities (localised disease and metastatic relapse) and for metastatic and pelvic osteosarcoma the 1st of March, 1997. These results are in the meantime published.

The 1st of June, 1999, we introduced together the ISG/SSG III-IV protocols for treatment of non-metastatic and high-risk Ewing’s family tumors. These studies are still ongoing.

During this meeting we will focus on agreement between the Italian and Scandinavian sarcoma groups with respect to Ewing’s sarcoma clinical studies, basic research in bone sarcomas, EUROBOSS, Ewing’s sarcoma basic studies and evaluation of response (histological and radiological). On the other hand we will also discuss our disagreements (definition of high risk soft tissue sarcoma patients (prognostic factors), adjuvant treatment in soft tissue sarcoma, chemotherapy modalities in sarcoma, adjuvant studies in GIST, association of high dose busulphan and total lung irradiation, and finally surgical margins). Free papers on tumor biology, combined treatment and diagnosis and outcome will be presented.

We hope that all ISG, SSG and other European sarcoma groups members learn to know each other better and deepen our collaboration for the future in a beautiful Italian environment in Cetraro.

Piero Picci
Chairman of the Italian Sarcoma Group

Thor A Alvegård, Henrik Bauer
Chairmen of the Scandinavian Sarcoma Group
Wednesday April 26, 2006

20.00 Welcome cocktail

Thursday April 27, 2006

08.30–11.30 We agree
Chairmen: P. Picci, Bologna, T. Alvegård, Lund
08.30 ISG/SSG I, S. Ferrari, Bologna, S. Smeland, Oslo
08.50 ISG/SSG II, A. Brach del Prever, Turin, S. Smeland, Oslo
09.10 ISG/SSG III, F. Fagioli, Torin, S. Smeland, Oslo
09.30 ISG/SSG IV, A. Tienghi, Ravenna
09.50 EUROBOSS, S. Ferrari, Bologna
10.10 EURELOS, S. Ferrari, Bologna
10.30 Molecular targeted therapy in chordoma, P. Casali, Milan
10.50 GIST natural history, AP. Dei Tos, Treviso
11.10 Discussion

11.30–15.30 Lunch and free activities

16.30–18.00 Case discussion
Chairmen: P. Casali, Milan, J. Åhlén, Stockholm
16.30 Trabectedin as a neoadjuvant in myxoid liposarcoma, F. Grosso, Milan
16.40 Primary leiomyosarcoma of vena cava, A. Gronchi, Milan
16.50 Immune accessory cell sarcoma, F. Grosso, Milan
17.00 Intimal sarcoma, S. Stacchiotti, Milan
17.10 GIST in NF1, E. Tamborini, Milan
17.20 L1 Epithelioid sarcoma of the penis
C. Sangalli, A. Gronchi, L. Lozza, E. Orlandi, C. Fallai, P. Casali, C. Piovesan, V. Monjoi, P. Olmi, Milan

17.30 L2 A rare case of indication for en bloc resection for metastatic tumor of the spine
D. Iantorno, A. Gasbarrini, L. Mirabile, S. Boriani, Bologna

17.40 L3 Surgery and postoperative radiotherapy for simultaneous occurrence of malignant fibrous histiocytoma and olfactory neuroblastoma of paranasal sinuses
E. Orlandi, C. Sangalli, M. Rossi, M. Palazzi, S. Riccio, G. Cantù, C.L. Solero, V. Mongioj, P. Olmi, Milan

17.50 Discussion

18.00–18.30 Coffee break

18.30–20.00 Free papers
Chairmen: K. Sundy-Hall, Oslo, M. Aglietta, Turin

18.30 L4 New cancer-specific fusion genes in endometrial stromal sarcoma
F. Micci, Oslo, I. Panagopoulos, Lund, B. Bjerkehagen, and S. Heim, Oslo

18.40 L5 Inhibitor effect of osteosarcoma cell lines on dendritic cells Types 1 (DC1) and 2 (DC2)
F. Carraro, A. Palmero, M. Muraro, D. Rustichelli, I. Ferrero, E. Madon, F. Fagioli, Turin

18.50 L6 Nutlin 3a in combination with prevailing chemo-therapy gives promising results in sarcoma cell lines
H. Oma Ohnstad, P. Noordhuis, L. T. Vassilev, O. Myklebost, Oslo
19.00  L7  Comparative genomic hybridization profiling in pleomorphic soft tissue sarcomas
P. Francis, J. Fernebro, A. Carneiro, A. Rydholm, M. Åkerman, M. Nilbert, Lund

19.10  L8  Luciferase imaging of a Balb/c mouse syngenic metastatic osteosarcoma model
S. Miretti, Turin, M. Cilli, Genova, R. Taulli, I. Roato, P. Buracco, Turin, A. Albini, Torin, R. Ferracini, Turin

19.20  L9  Identification of the NG2 Proteoglycan-Collagen type VI Interplay as a Pro-Metastastic Factor in soft tissue sarcomas and design of approaches for the exploitation of NG2 as an immunotherapeutic target

19.30  L10 Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels as new marker for drug-induced cardiotoxicity

19.40  L11 Increased risk of malignancies in a population-based study of 820 soft tissue sarcoma patients

19.50  Discussion

20.30  Dinner in the cellar
Friday April 28, 2006

08.00–11.30  **We disagree**  
Chairmen: S. Ferrari, Bologna, S. Smeland, Oslo

08.15  L12 The Scandinavian Sarcoma Group (SSG) experiences from ongoing intergroup trial EURAMOS 1  
A. Bladström, J. Ceberg, C. Danewid, M. Eriksson,  
E. Johansson, M. Marotta, E-M Olofsson, V. Samuelsson,  
T. Alvegård, Lund

08.30  L13 Status of the European and American Osteosarcoma Study, EURAMOS-1  
S. Smeland, Oslo, M. Eriksson, Lund, T. Boeling,  
Helsinki, O. S. Nielsen, M. Tarkkanen, Aarhus,  
A. Bladström, T. Alvegård, Lund

08.45  ISG/OS 1, S. Ferrari, Bologna

09.00  GIST studies, P. Casali, Milan

09.15  Surgery of residual disease in GIST, A. Gronchi, Milan

09.30  L14 A Scandinavian Sarcoma Group (SSG) treatment protocol for adult patients with high-risk soft tissue sarcoma of the extremities and trunk wall  
K. Sundby Hall, Oslo – for the SSG working group

09.45–10.15  **Coffee**

10.15  Update of soft tissue sarcoma studies in Italy,  
A. Gronchi, Milan

10.30  The role of surgical margins in soft tissue sarcomas,  
A. Gronchi, Milan

10.45  Association of high dose busulphan and TLI,  
A. Tienghi, Ravenna

11.00  Extraskeletal Ewing’s family tumors, P. Dileo, Milan

11.15  Discussion

11.30–15.30  **Lunch and free activities**
16.30–18.00 **Ewing’s Sarcoma–Symposium**  
Chairmen: P. Picci, Bologna, S. Smeland, Oslo

16.30 L15 Prognosis and therapeutic targets in the Ewing family of tumors - sixth framework programme- 1st year update  
K. Scotlandi, Bologna, P. Picci, A. Bernard, F. van Valen, S. Knuutila, A. Llombart-Bosch, H. Kovar, B. Perbal, Cl. Malvy, M. Gottikh

17.00 Treatment of Ewing’s Sarcoma – The EURO-Ewing’s experience. The past and the future  
M. Paulussen, Basel

17.40 Discussion

18.00–18.30 **Coffee break**

**18.30–20.00 Free papers**  
Chairmen: A. Comandone, Turin, A. Rydholm, Lund

18.30 L16 Soft tissue sarcoma in adolescents and young adults  
B. Malmer, A. S. Johansson, K. Johansson, R. Löwenberg, H. Bauer, M. Erlanson, Umeå

18.40 L17 Most benign lesions around the knee do not need filling following curettage?  

18.50 L18 Multifocal ossifying fibromyxoid tumor, benign or malignant? Follow up using scintigraphy?  
R. Löfvenberg, M. Erlanson, M. Hanson, I. Johansson, C. Ström, Umeå

19.00 L19 Successful treatment of a child with a Ewing-like, t(15;19)-positive bone tumor: Implications for the diagnostic impact of genetic analyses  
F. Mertens, T. Wiebe, C. Adlercreutz, N. Mandahl, Lund, C. A. French, Boston
19.10  L20  Specific T-cell therapy for very high risk osteosarcoma patients
        F. Carraro, A. Palmero, M. Muraro, M. Berger,
        M. Mereuta, E. Madon, F. Fagioli, Turin

19.20  L21  Liposarcoma – outcome based on 243 patients from the SSG register
        K. Engström, P. Bergh, Gothenburg, P. Gustafson, Lund,
        O. Wahlström, Linköping, R. Löfvenberg, Umeå, K.
        Sundby Hall, Oslo, C. Trovik, Bergen, H. C. F. Bauer,
        Stockholm

19.30  L22  Results from the Scandinavian Sarcoma Group, SSG XIV, Osteosarcoma trial
        S. Smeland, Oslo, T. Wiebe, Lund, Ø. S. Bruland, Oslo,
        T. Boeling, Helsinki, O. Brosjö, Stockholm, T. A.
        Alvegaard, Lund

19.40  Discussion

20.30  Gala dinner
Free papers

Chairmen: H. Bauer, Stockholm, A. Gronchi, Milan

08.30  L23  GIST mainly has an infiltrative growth pattern supporting surgery with wide margins whenever possible
J. Åhlen, Stockholm

08.40  L24  Chondrosarcoma in patients with hereditary multiple exostoses
S. Skjeldal, G. Follerås, O. Zaaikova, O-J. Norum, I. Taksdal and B.1 Bjerkehagen, Oslo

08.50  L25  Dedifferentiated chondrosarcoma – results of a European wide study
R. Grimer, Birmingham – on behalf of the members of EMSOS

09.00  L26  What is the optimum follow up regime for sarcoma patients?
R. Grimer, C. Gerrand, Birmingham

09.10  L27  Quality of life and mental distress in survivors of extremity bone sarcoma

09.20  L28  Psychological support during chemotherapy in patients with sarcomas
09.30 L29 Terminal phase in patients with advanced sarcomas: a perspective study for a better assistance

09.40 L30 The Scandinavian Sarcoma Group Skeletal Metastasis Registry. Functional outcome and pain after surgery for bone metastases in the pelvis and extremities

09.50 L31 A new strategy for preoperative radiotherapy of retroperitoneal sarcoma
A. Bossi, E. Van Limbergen, I. De Wever, Leuven

10.00 Discussion

10.30–11.00 Coffee break

11.00–12.00 ISG – Member meeting
SSG – Member meeting

12.00–12.30 Closure of the meeting

12.30 Lunch